- Home
- RSSS vs CHRS Comparison
RSSS vs CHRS Comparison
Compare RSSS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSSS
- CHRS
- Stock Information
- Founded
- RSSS 2006
- CHRS 2010
- Country
- RSSS United States
- CHRS United States
- Employees
- RSSS N/A
- CHRS N/A
- Industry
- RSSS Business Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RSSS Consumer Discretionary
- CHRS Health Care
- Exchange
- RSSS Nasdaq
- CHRS Nasdaq
- Market Cap
- RSSS 90.6M
- CHRS 84.2M
- IPO Year
- RSSS N/A
- CHRS 2014
- Fundamental
- Price
- RSSS $2.95
- CHRS $0.90
- Analyst Decision
- RSSS
- CHRS Buy
- Analyst Count
- RSSS 0
- CHRS 3
- Target Price
- RSSS N/A
- CHRS $4.68
- AVG Volume (30 Days)
- RSSS 44.9K
- CHRS 1.2M
- Earning Date
- RSSS 05-08-2025
- CHRS 08-07-2025
- Dividend Yield
- RSSS N/A
- CHRS N/A
- EPS Growth
- RSSS N/A
- CHRS N/A
- EPS
- RSSS N/A
- CHRS N/A
- Revenue
- RSSS $48,753,578.00
- CHRS $272,251,000.00
- Revenue This Year
- RSSS $12.42
- CHRS N/A
- Revenue Next Year
- RSSS $7.47
- CHRS $106.56
- P/E Ratio
- RSSS N/A
- CHRS N/A
- Revenue Growth
- RSSS 14.85
- CHRS 19.87
- 52 Week Low
- RSSS $2.32
- CHRS $0.66
- 52 Week High
- RSSS $4.24
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- RSSS 54.66
- CHRS 59.04
- Support Level
- RSSS $2.94
- CHRS $0.73
- Resistance Level
- RSSS $3.10
- CHRS $0.82
- Average True Range (ATR)
- RSSS 0.09
- CHRS 0.04
- MACD
- RSSS 0.02
- CHRS 0.02
- Stochastic Oscillator
- RSSS 62.45
- CHRS 88.02
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides a cloud-based SaaS research intelligence platform consisting of proprietary software and Internet-based interfaces. Its platform also allows customers to find and download digital versions of STM articles. Platforms and Transactions are packaged as a single solution that enables life science and other research-intensive organizations to speed up research and development activities. The company platform allows customers to initiate orders, manage transactions, automate authentication, obtain reports, and connect seamlessly to corporate intranets.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.